Kymera Therapeutics Inc.

26.38
1.14 (4.54%)
At close: Apr 02, 2025, 3:59 PM
26.06
-1.21%
After-hours: Apr 02, 2025, 05:07 PM EDT

Kymera Therapeutics Statistics

Share Statistics

Kymera Therapeutics has 64.94M shares outstanding. The number of shares has increased by 5.84% in one year.

Shares Outstanding 64.94M
Shares Change (YoY) 5.84%
Shares Change (QoQ) 0.28%
Owned by Institutions (%) 93.62%
Shares Floating 53.96M
Failed to Deliver (FTD) Shares 4.67K
FTD / Avg. Volume 0.8%

Short Selling Information

The latest short interest is 8.35M, so 12.9% of the outstanding shares have been sold short.

Short Interest 8.35M
Short % of Shares Out 12.9%
Short % of Float 15.19%
Short Ratio (days to cover) 15.84

Valuation Ratios

The PE ratio is -13.49 and the forward PE ratio is -12.6. Kymera Therapeutics's PEG ratio is -0.74.

PE Ratio -13.49
Forward PE -12.6
PS Ratio 64.14
Forward PS 2.7
PB Ratio 3.61
P/FCF Ratio -14.56
PEG Ratio -0.74
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Kymera Therapeutics.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 7.53, with a Debt / Equity ratio of 0.11.

Current Ratio 7.53
Quick Ratio 7.53
Debt / Equity 0.11
Debt / EBITDA -0.41
Debt / FCF -0.42
Interest Coverage -1050.74

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $250.38K
Profits Per Employee $-1.19M
Employee Count 188
Asset Turnover 0.05
Inventory Turnover n/a

Taxes

Income Tax 0
Effective Tax Rate 0%

Stock Price Statistics

The stock price has increased by -32.97% in the last 52 weeks. The beta is 2.23, so Kymera Therapeutics's price volatility has been higher than the market average.

Beta 2.23
52-Week Price Change -32.97%
50-Day Moving Average 35.37
200-Day Moving Average 41.38
Relative Strength Index (RSI) 24.49
Average Volume (20 Days) 586.58K

Income Statement

In the last 12 months, Kymera Therapeutics had revenue of 47.07M and earned -223.86M in profits. Earnings per share was -2.98.

Revenue 47.07M
Gross Profit 47.07M
Operating Income -261.63M
Net Income -223.86M
EBITDA -216.24M
EBIT -223.61M
Earnings Per Share (EPS) -2.98
Full Income Statement

Balance Sheet

The company has 120.26M in cash and 87.76M in debt, giving a net cash position of 32.49M.

Cash & Cash Equivalents 120.26M
Total Debt 87.76M
Net Cash 32.49M
Retained Earnings -754.61M
Total Assets 978.03M
Working Capital 442.5M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -194.5M and capital expenditures -12.84M, giving a free cash flow of -207.34M.

Operating Cash Flow -194.5M
Capital Expenditures -12.84M
Free Cash Flow -207.34M
FCF Per Share -2.76
Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of -555.82% and -475.57%.

Gross Margin 100%
Operating Margin -555.82%
Pretax Margin -475.57%
Profit Margin -475.57%
EBITDA Margin -459.37%
EBIT Margin -555.82%
FCF Margin -440.47%

Dividends & Yields

KYMR does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for KYMR is $57, which is 125.9% higher than the current price. The consensus rating is "Buy".

Price Target $57
Price Target Difference 125.9%
Analyst Consensus Buy
Analyst Count 13
Stock Forecasts

Scores

Altman Z-Score 6.25
Piotroski F-Score 4